HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleural drainage followed by chemotherapy containing rituximab

28Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

The present patient was diagnosed as having human herpes virus-8 (HHV-8)/ Kaposi sarcoma herpes virus (KSHV)-negative and CD20-positive primary effusion lymphoma (PEL) of the right-sided pleural effusion. After pleural drainage, malignant cells disappeared spontaneously in a small amount of the remaining pleural effusion without chemotherapy. The patient was treated with six cycles of chemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. He has been in complete remission for more than 22 months. It is suggested that effusion drainage followed by chemotherapy containing rituximab is a potential treatment strategy for patients with HHV-8/KSHV-negative and CD20-positive PEL. © 2008 The Japanese Society of Internal Medicine.

Cite

CITATION STYLE

APA

Terasaki, Y., Okumura, H., Saito, K., Sato, Y., Yoshino, T., Ichonohasama, R., & Ishida, Y. (2008). HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleural drainage followed by chemotherapy containing rituximab. Internal Medicine, 47(24), 2175–2178. https://doi.org/10.2169/internalmedicine.47.1565

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free